Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company specializing in MasterKey therapies for cancer treatment, has announced its upcoming participation in two major investor conferences.

The company's President and CEO, Mark Velleca, M.D., Ph.D., will present at the following events:

• 24th Annual Needham Virtual Healthcare Conference - April 7, 2025, at 3:00 PM ET
• Stifel 2025 Virtual Targeted Oncology Forum - April 8, 2025, at 1:00 PM ET

Both presentations will be accessible via webcast on the investor relations section of Black Diamond Therapeutics' website, with replays available for 90 days.

News Market Reaction – BDTX

-3.73%

-3.73% Session move

In the trading session that priced this news, BDTX declined 3.73%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

• 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025
• Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com

FAQ

When is Black Diamond Therapeutics (BDTX) presenting at the Needham Healthcare Conference 2025?

BDTX will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 3:00 PM ET.

How long will BDTX's investor conference webcasts be available for replay?

The webcasts will be archived and available for replay on Black Diamond Therapeutics' website for 90 days.

What investor conferences is BDTX participating in during April 2025?

BDTX is participating in the Needham Virtual Healthcare Conference (April 7) and the Stifel Virtual Targeted Oncology Forum (April 8).

Where can investors access Black Diamond Therapeutics' (BDTX) conference presentations?

Investors can access the webcasts through the investor relations section of BDTX's website at www.blackdiamondtherapeutics.com.

What type of cancer therapies is BDTX developing?

BDTX is developing MasterKey therapies that target families of oncogenic mutations in cancer patients.